版本:
中国

BRIEF-Avexis and Regenxbio announce new exclusive worldwide licenses

June 7 Avexis Inc:

* Avexis and Regenxbio announce new exclusive worldwide licenses for the treatment of two rare neurological monogenic disorders using NAV AAV9 vector

* Avexis - ‍Regenxbio to receive upfront payment upon execution, ongoing fees, milestone payments & royalties on net sales of products incorporating NAV AAV9 vector​

* Avexis Inc- intends to move forward with initiating ind-enabling studies in both RTT and ALS, plans to provide details on programs in 2h 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐